DUBLIN – Glaxosmithkline plc is adding a second cytokine-targeting antibody to its respiratory disease portfolio by in-licensing Johnson & Johnson's CNTO 7160, a phase I antibody that targets the interleukin-33 (IL-33) receptor. The deal is worth up to £175 million (US$229 million), comprising an undisclosed up-front payment plus milestones covering development and first commercial sales. J&J would also gain tiered sales royalties, should the product gain approval, plus additional payments tied to its sales performance.